Use of an additional BZD after
night-time awakenings
At baseline, 12 participants in the CRM group and eight in
the placebo group reported taking an additional BZD after
awakening each night (P = 0.593). During the withdrawal
period, the frequency of taking an additional BZD during
the night decreased in both groups but there was no significant
difference between the groups (Table 4). At the
end of the follow-up periods, the reduction in additional
BZD use for night-time awakenings, compared with thebaseline, was still significant in both groups. However, the
participants in the CRM group more frequently took an
additional BZD than did those in the placebo group
(COR = 6.6, 95% CI 1.7, 24.9, P = 0.006) (Table 4).